Alector is a biotechnology company focused on developing novel therapeutics for neurodegenerative diseases. Their approach, termed immuno-neurology, utilizes insights from immunology, neurology, and human genetics to create therapies that harness the body's innate healing potential. Alector is driven by the mission to transform the treatment of conditions such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). They emphasize a culture of curiosity and collaboration, aiming to provide first-in-class therapeutics that make a profound impact on patients' lives.